Skip to main content
SpringerLink
Log in

IFN-Β-1a prescriptions grow at the expense of other MS therapies

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

IFN-Β-1a prescriptions grow at the expense of other MS therapies. Pharmacoecon. Outcomes News 393, 11 (2002). https://doi.org/10.1007/BF03280010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03280010

Keywords

Search

Navigation